We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
Read MoreHide Full Article
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).
Corbus’ share price has gained 17.8% in the past one month, outperforming the Zacks classified Medical-Drugs industry which has witnessed a gain of 2.5% gain in the same time frame.
The Phase II trial is a multi-center, double-blinded, randomized, placebo-controlled study. The main aim of the trial was to test safety and tolerability of JBT-101 in adults with CF who had forced expiratory volume in 1 second (FEV1) percent predicted at least 40%, without regard to their CFTR mutation, infecting pathogen, or baseline treatment. The company expects to report top-line data from the study in first-quarter 2017.
Resunab, is Corbus’ lead product candidate. It is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and fibrotic processes by triggering an endogenous pathway called "Resolution of Inflammation.”
Notably, resunab has been granted Fast Track status and Orphan Drug Designation for the treatment of CF, by the FDA and the EU, respectively. Additionally, resunab is currently being evaluated in a Phase II, 12-month open label extension study in systemic sclerosis, a Phase II study in skin-predominant dermatomyositis, while another Phase II study in systemic lupus erythematosus (SLE) is expected to start in first-quarter 2017.
Last month, the company reported positive top-line data results from its Phase II study in diffuse cutaneous systemic sclerosis ("systemic sclerosis"), displaying clear signal of clinical benefit with JBT-101. The candidate outperformed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo.
Key Picks
Investors looking for some well-positioned stocks in the health care sector could consider Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 88.3% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 13.7% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 28.9% year to date.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).
Corbus’ share price has gained 17.8% in the past one month, outperforming the Zacks classified Medical-Drugs industry which has witnessed a gain of 2.5% gain in the same time frame.
The Phase II trial is a multi-center, double-blinded, randomized, placebo-controlled study. The main aim of the trial was to test safety and tolerability of JBT-101 in adults with CF who had forced expiratory volume in 1 second (FEV1) percent predicted at least 40%, without regard to their CFTR mutation, infecting pathogen, or baseline treatment. The company expects to report top-line data from the study in first-quarter 2017.
Resunab, is Corbus’ lead product candidate. It is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and fibrotic processes by triggering an endogenous pathway called "Resolution of Inflammation.”
Notably, resunab has been granted Fast Track status and Orphan Drug Designation for the treatment of CF, by the FDA and the EU, respectively. Additionally, resunab is currently being evaluated in a Phase II, 12-month open label extension study in systemic sclerosis, a Phase II study in skin-predominant dermatomyositis, while another Phase II study in systemic lupus erythematosus (SLE) is expected to start in first-quarter 2017.
Last month, the company reported positive top-line data results from its Phase II study in diffuse cutaneous systemic sclerosis ("systemic sclerosis"), displaying clear signal of clinical benefit with JBT-101. The candidate outperformed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo.
Key Picks
Investors looking for some well-positioned stocks in the health care sector could consider Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 88.3% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 13.7% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 28.9% year to date.
CORBUS PHARMACT Price
CORBUS PHARMACT Price | CORBUS PHARMACT Quote
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades>>